Next generation sequencing (NGS) refers to high-throughput methods for DNA sequencing that are not Sanger-based. NGS technology has largely superseded Sanger sequencing in academic or genome research and is increasingly being applied in clinical practice.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Next Generation Sequencing (NGS) Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Next Generation Sequencing (NGS) Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to :
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Next Generation Sequencing (NGS) Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4bases SA
- AccuraGen Inc
- ACT Genomics Co LTD
- Adaptive Biotechnologies Corp
- Almac Diagnostic Services Ltd
- Amoy Diagnostics Co Ltd
- AnchorDx Medical Co Ltd
- ArcherDx Inc
- Berry Oncology Corp
- BGI Genomics Co Ltd
- Biocartis Group NV
- Biodesix Inc
- BioLink
- bioTheranostics Inc
- Boston University
- Buhlmann Laboratories AG
- Burning Rock Biotech Ltd
- Cardiff Oncology Inc
- CCM Biosciences Inc
- Cerba HealthCare SAS
- Cyclomics BV
- DCGen Co Ltd
- Eiken Chemical Co Ltd
- Epic Sciences Inc
- Epigenomics AG
- FBB Biomed Inc
- Feng Biosciences Inc
- First Genetics JCS
- Flomics Biotech
- Foundation Medicine Inc
- Gencurix Inc
- GeneCast Biotechnology Co Ltd
- Geneseeq Technology Inc
- Genetron Health (Beijing) Co Ltd
- Genomic Health Inc
- GigaGen Inc
- HaploX Biotechnology Co Ltd
- Haystack Oncology Inc
- HTG Molecular Diagnostics Inc
- Illumina Inc
- Immunovia AB
- Inivata Ltd
- Insight Genetics Inc
- Invivoscribe Inc
- IvyGene Diagnostics
- Laboratory Corp of America Holdings
- Leto Laboratories Co Ltd
- Lucence Diagnostics Pte Ltd
- MedySapiens Inc
- Mega Genomics Ltd
- Micronoma
- MolecularMD Corp
- NGeneBio Co Ltd
- Novigenix SA
- Novomics Co Ltd
- NuGEN Technologies Inc
- NuProbe Inc
- Oncodiag
- OncoDNA SA
- OncoSpire Genomics
- OrigiMed Inc
- Otsuka Medical Devices Co Ltd
- Pasteur Institute
- Personal Genome Diagnostics Inc
- Pillar Biosciences Inc
- Predicine Inc
- Predictive Biosciences Inc (Inactive)
- PT PathGen Diagnostik Teknologi
- Qiagen NV
- Quantgene Inc
- Queen's University
- RealSeq Biosciences Inc
- Rhodx Inc
- Roche Diagnostics International Ltd
- SeqOne SAS
- Silicon Biosystems S.p.A.
- Sophia Genetics SA
- Sostos LLC
- Spectrum Solutions LLC
- Sysmex Corp
- Sysmex Inostics GmbH
- Tempus Health Inc
- Tempus Labs Inc
- Thermo Fisher Scientific Inc
- Trivitron Healthcare Pvt Ltd
- TwinStrand Biosciences Inc
- University of Chicago
- University of Michigan Rogel Cancer Center
- University of Texas Health Science Center at Houston
- Veracyte Inc
- Vyant Bio Inc (Inactive)